Finally, we utilized in silico analysis of FDA-approved drugs and identified angiotensin-converting enzyme (ACE) inhibitors as a specific class of antihypertensive drugs that protect against sunitinib-induced vascular dysfunction both in vitro and in vivo, all the while preserving the efficacy of sunitinib against tumor growth. The gene discussed is ACE; the disease is neoplasm.